Lexaria Bioscience Corp.
LEXX
$4.52
-$1.35-22.93%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.99M | -1.45M | -1.60M | -2.70M | -3.79M |
| Total Depreciation and Amortization | 26.80K | 26.60K | 24.20K | 28.60K | 38.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 92.80K | 73.90K | 96.40K | 348.70K | 511.20K |
| Change in Net Operating Assets | 236.50K | -814.40K | 490.30K | -323.90K | -344.10K |
| Cash from Operations | -1.64M | -2.16M | -984.10K | -2.64M | -3.58M |
| Capital Expenditure | 0.00 | -40.80K | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -27.10K | -13.10K | -5.10K | -157.90K | -19.40K |
| Cash from Investing | -27.10K | -53.90K | -5.10K | -157.90K | -19.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 3.04M | 3.47M | 0.00 | 1.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 3.04M | 3.47M | 0.00 | 1.69M |
| Foreign Exchange rate Adjustments | 9.00K | 20.60K | -5.70K | 10.70K | 37.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.65M | 846.90K | 2.48M | -2.79M | -1.88M |